Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer

Summary

The goal of this phase I-II clinical research study is to find the highest safe dose of XRP9881 and capecitabine that can be given in combination in the treatment of metastatic breast cancer in patients who have been previously treated by taxanes and anthracyclines. The safety and effectiveness of this combination will also be studied. Patients participating in the study will be asked to give additional blood samples to look at the level of study drugs in the blood.

Timeline

Start

2006-08

Primary completion

2009-03

Completion

2009-03

Drugs

Indications